Pain management in osteoarthritis: The role of COX-2 inhibitors

Journal of Rheumatology

Volumn 24, Issue SUPPL. 49, 1997, Pages 20-24

  Lane, Nancy E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclooxygenase 2 inhibition; Osteoarthritis; Pain; Treatment

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE DYSFUNCTION; TOOTH PAIN; TREATMENT OUTCOME;

EID: 0030849721     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scott JC, Hochberg MC: Arthritic and other musculoskeletal diseases. In: Brownson RC, Remington PL, Davis JL, eds. Chronic Disease Epidemiology and Control. Washington, DC: American Public Health Association, 1993.
2. Lawrence RC, Bremner JM, Bier F: Osteoarthritis, prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966;25:1-24.
3. Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1987;16:427-41.
4. Yelin EH: The economic impact of osteoarthritis. In: Baker JR, Brandt KD, eds. Reappraisal of the Management of Patients with Osteoarthritis. Springfield, Mass: Scientific Therapeutics Information Inc., 1993:1-92.
5. Gramas DA, Lane NE: Osteoarthritis. In: Weisman MH, Weinblatt ME, eds. Treatment of the Rheumatic Diseases. Philadelphia: WB Saunders, 1995:286-311.
6. Altman RD, Asch E, Bloch D, et al: Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
7. Hamerman D: The biology of osteoarthritis. N Engl J Med 1989;320:1322-30.
8. Hugenberg ST, Myers SL, Brandt KD, Ryan SI: Synovitis does not produce response to nonsteroidal anti-inflammatory drug therapy in knee osteoarthritis (abstr). Arthritis Rheum 1991;(suppl)34:S84.
9. Myers SL, Flusser D, Brandt KD, Heck DA: Prevalence of cartilage shards in synovium and their association with synovitis in patients with early and endstage osteoarthritis. J Rheumatol 1992; 19:1247-51.
10. Mankin HJ: Clinical features of osteoarthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology, 4th ed. Philadelphia: WB Saunders, 1993:1374-84.
11. Hochberg MC, Altman R, Brandt KD, et al: Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
12. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563-72.
13. Langman MJS: Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med 1988;(suppl)84:2A:15-9.
14. Dieppe P, Cushnaghan J, Jasani MK, McCrae F, Watt I: A two year placebo controlled trial of nonsteroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993;32:595-600.
15. Griffin MR, Piper JM, Doughtery JR, Snowden M, Ray WA: Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
16. Griffin MR, Ray WA, Schaffner W: Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
17. Gabriel S, Jaakkimainen L, Bombardier C: Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-91.
18. Lichtenstein DR, Syngal S, Wolfe MM: Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: The double-edged sword. Arthritis Rheum 1995;38:5-18.
19. Fries JF: NSAID gastropathy: The second most deadly disease? Epidemiology and risk appraisal. J Rheumatol 1991;(suppl)28:6-10.
20. Silverstein FE, Graham DY, Senior JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double blind, placebo controlled trial. Ann Intern Med 1995;123:241-9.
21. Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs: Differences and similarities. N Engl J Med 1991;324:1716-25.
22. Barradell LB, Whittington R, Benfield P: Misoprostol: Pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. Pharmacoeconomics 1991;3:140-71.
23. Gabriel SE, Jaakkimainen RL, Bombardier C: The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:441-59.
24. Wilcox CM, Shalek KA, Cotsonis MA: Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994;154:42-6.
25. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI: Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1997;325:87-91.
26. Williams HK, Ward JR, Egger MJ, et al: Comparison of naproxen and acetaminophen in the two-year study of the treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206.
27. Vane JR, Botting RM: Overview - Mechanisms of action of anti-inflammatory drugs. In: Vane JR, Botting J, Botting R, eds. Improved Non-steroid Anti-inflammatory Drugs: COX-2 Enzyme Inhibitors. Netherlands: Kluwer, 1996:1-27.
28. Needleman P: In search of better NSAIDs. 9th International conference on prostaglandins and related compounds. Florence, Italy, 1994:6-10.
29. Seibert K, Zhand Y, Leahy K, et al: Pharmacologic and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:1201-7.
30. Reitz DB, Li JJ, Norton MB, et al: Selective cyclo-oxygenase inhibitors: Novel 1,2 diarylcyclo-pentenes are potent orally active COX-2 inhibitors. J Med Chem 1994;37:3878-81.